



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARG5


Last Trade:	0.17
Trade Time:	2:40 PM ET Oct 23, 2017
Change:	0.00 (0.179%)
Day Range	0.17 - 0.17
52-Week Range	0.16 - 5.68
Volume	1,130,965

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 26, 2017
[Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors](#)
- Sep 19, 2017
[Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress](#)
- Sep 12, 2017
[Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress](#)
- Sep 6, 2017
[Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir](#)
- Aug 21, 2017
[Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress](#)

Financials [\[View all \]](#)

- Mar 16, 2017
[Annual Report \(10-K\)](#)
- Jul 6, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 9, 2017
[Quarterly Report \(10-Q\)](#)
- May 10, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016
[Quarterly Report \(10-Q\)](#)